News

  • 11 August 2008

    Kuros Biosurgery AG announced today the results of the one-month follow-up of a Phase IIa clinical trial assessing the potential of KUR-212 (Viz.I-020502), its novel platelet-derived growth factor (PDGF) and fibrin combination product, for the treatment of patients with burns requiring autologous meshed skin grafting. In the one-month follow-up of this Phase IIa study, there were no treatment-related adverse events, meeting the primary endpoint (safety) of the study.

  • 6 June 2008

    CREABILIS therapeutics SpA, an emerging specialty pharmaceutical company focused on dermatology, today announces that it has raised a total of €20 million in a Series A round of funding. The financing was led by Sofinnova Partners, which was joined in the funding round by NeoMed Management. Representatives of both Sofinnova and NeoMed will be joining the CREABILIS therapeutics's Board following this fund raising.

  • 9 May 2008

    EUSA Pharma announced today that it has completed its acquisition of Cytogen Corporation, following the approval of Cytogen’s shareholders at a special meeting on 8 May.

  • 18 February 2008

    EUSA Pharma today today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales. As part of the agreement EUSA will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex Inc. GSK will fund and conduct all future development, production and commercialization of the product.

  • 22 January 2008

    Novexel, the pharmaceutical company focused on the discovery and development of novel antibacterials and anti-fungals, today announces that it has entered into an agreement with Forest Laboratories Holdings Limited, a wholly owned subsidiary of Forest Laboratories, Inc. (NYSE: FRX), for the development, manufacture and commercialization of Novexel's novel intravenous beta lactamase inhibitor, NXL104 in combination with Forest’s ceftaroline. NXL104 is designed to be co- administered with select antibiotics to enhance their spectrum of activity.